2,6-bis(2,2-dimethylpropyl)phenol | 81216-68-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 2,6-bis(2,2-dimethylpropyl)phenol
• 英文别名: 2,6-di-tert-butylmethylphenol；2,6-bis(1,1-dimethyl ethyl) methyl-phenol
• CAS: 81216-68-4
• 化学式: C₁₆H₂₆O
• 分子量: 234.382
• InChiKey: KWADCQUPPUPHGW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  环己酮 、 特戊醛 在 二氯二茂锆 作用下， 反应 8.0h， 以37%的产率得到2,6-bis(2,2-dimethylpropyl)phenol
  参考文献：
  名称：

  Facile synthesis of 2,6-dialkylphenols by cross-aromatization of cyclohexanones with aldehydes catalyzed by zirconocene complexes

  摘要：

  DOI：

  10.1021/jo00256a061

文献信息

• PHENYL (METH)ACRYLATE PRODUCTION METHOD AND PHENYL (METH)ACRYLATE COMPOSITION
  申请人：MITSUBISHI RAYON CO., LTD.

  公开号：US20160244396A1

  公开（公告）日：2016-08-25

  Provided is a method that can produce phenyl(meth)acrylate inexpensively and at high yields. The phenyl(meth)acrylate production method of the present invention reacts (meth)acrylic acid with carbonic acid diphenyl. Further, the phenyl(meth)acyrlate composition of the present invention contains 90-99.999 wt % phenyl(meth)acrylate and 0.001-10% carbonic acid diphenyl. Or, the phenyl(meth)acrylate composition of the present invention contains 90-99.999 wt % phenyl(meth)acrylate and 0.001-10 wt % of a specified compound.

  提供的是一种可以以低成本高收率生产苯基(甲基)丙烯酸酯的方法。本发明的苯基(甲基)丙烯酸酯生产方法是将(甲基)丙烯酸与二苯基碳酸反应。此外，本发明的苯基(甲基)丙烯酸酯组合物含有90-99.999重量%的苯基(甲基)丙烯酸酯和0.001-10%的二苯基碳酸。或者，本发明的苯基(甲基)丙烯酸酯组合物含有90-99.999重量%的苯基(甲基)丙烯酸酯和0.001-10重量%的特定化合物。
• DELIVERY OF NUCLEIC ACID COMPLEXES FROM MATERIALS INCLUDING NEGATIVELY CHARGED GROUPS
  申请人：McGonigle Joseph Schmidt

  公开号：US20090263449A1

  公开（公告）日：2009-10-22

  Embodiments of the invention include devices and methods for the controlled elution of nucleic acid delivery complexes. In an embodiment, the invention includes a medical device including a substrate surface, a polymeric coating disposed on the surface, the polymeric coating coupled to the substrate surface through the reaction product of a photoreactive group; the polymeric coating comprising negatively charged species on the surface; and a plurality of nucleic acid delivery complexes disposed on the polymeric coating, the nucleic acid delivery complexes comprising a nucleic acid and a cationic carrier agent complexed to the nucleic acid. Other embodiments are included herein.

  本发明的实施例包括用于控制核酸递送复合物释放的装置和方法。在一种实施例中，本发明包括一种医疗器械，其中包括基底表面、沉积在表面上的聚合物涂层，聚合物涂层通过光反应性基团的反应产物与基底表面耦合；聚合物涂层在表面上包含负电荷物种；以及多个核酸递送复合物沉积在聚合物涂层上，核酸递送复合物包括与核酸形成复合物的阳离子载体剂。本发明还包括其他实施例。
• SYNTHESIS OF CATIONIC SILOXANE PREPOLYMERS
  申请人：Stanbro Jason K.

  公开号：US20080182956A1

  公开（公告）日：2008-07-31

  This application is directed toward an improved method of synthesizing cationic siloxane prepolymers as well as a specific cationic siloxane prepolymer having improved compatibility with monofunctional siloxanyl methacrylate monomers and medical devices containing the cationic siloxane prepolymer.

  这个应用程序旨在改进阳离子硅氧烷预聚物的合成方法，以及具有与单官能硅氧烷基甲基丙烯酸酯单体相容性改善的特定阳离子硅氧烷预聚物和含有阳离子硅氧烷预聚物的医疗器械。
• Therapeutic compounds for treating dyslipidemic conditions
  申请人：Jones Brian A.

  公开号：US20050239769A1

  公开（公告）日：2005-10-27

  The present invention relates to novel LXR ligands of Formula I and the pharmaceutically acceptable salts, esters and tautomers thereof, which are useful in the treatment of dyslipidemic conditions, particularly depressed levels of HDL cholesterol.

  本发明涉及公式I的新型LXR配体及其药学上可接受的盐、酯和互变异构体，其在治疗脂质代谢异常症状，特别是低下的高密度脂蛋白胆固醇水平中有用。
• Coatings with crystallized active agent(s) and methods
  申请人：Chappa A. Ralph

  公开号：US20060134168A1

  公开（公告）日：2006-06-22

  The present invention relates to coatings with crystallized active agent(s) and related methods. In an embodiment, the invention includes a method for coating a medical device including selecting a solvent and a polymer, selecting a concentration of an active agent of at least a certain amount of saturation, forming a coating composition having the selected concentration of the active agent, and applying the coating composition to the medical device. In an embodiment, the invention includes an elution control coating disposed on a medical device, the elution control coating including a polymer, and an active agent, wherein the active agent is at least about 80% crystallized within one week of being disposed on the medical device. In an embodiment, the invention includes a method for enhancing the formation of active agent crystals within a coating layer including forming a coating solution and adjusting the concentration of the active agent in the coating solution to reach some percentage of the active agent saturation point. In an embodiment, the invention includes a method of enhancing crystallization of an active agent, the method including forming a coating solution comprising a polymer, an active agent, and a solvent; applying the coating solution to a substrate; and increasing the rate of active agent nucleation within the coating.

  本发明涉及具有结晶活性剂的涂层及相关方法。在一种实施例中，本发明包括一种涂覆医疗器械的方法，包括选择溶剂和聚合物，选择至少一定饱和度的活性剂浓度，形成具有所选活性剂浓度的涂层组合物，并将涂层组合物涂覆在医疗器械上。在一种实施例中，本发明包括在医疗器械上设置的控制释放涂层，该控制释放涂层包括聚合物和活性剂，其中活性剂在被设置在医疗器械上的一周内至少约80%结晶。在一种实施例中，本发明包括一种增强涂层层内活性剂晶体形成的方法，包括形成涂层溶液并调整涂层溶液中活性剂的浓度以达到活性剂饱和点的一定百分比。在一种实施例中，本发明包括一种增强活性剂结晶的方法，该方法包括形成包括聚合物、活性剂和溶剂的涂层溶液；将涂层溶液涂覆在基底上；并增加涂层内活性剂成核的速率。